Alopecia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast

Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss. The host immune system targets anagen hair follicles. The primary goal of treatment is to stimulate hair growth by alleviating the inflammation at sites of hair loss. Topical / intralesional corticosteroids and topical immunotherapy are commonly prescribed for AA. Since 2022, the FDA and EC have approved the JAK inhibitors baricitinib (Eli Lilly) and ritlecitinib (Pfizer) for severe AA. In July 2024, the FDA approved a third JAK inhibitor for AA: Sun Pharma’s deuruxolitinib. The late-phase pipeline for this indication is small, consisting of an investigational JAK inhibitor and a novel botanical drug. In this report, we provide an analysis of AA epidemiology, current disease management, unmet needs, and the clinical and commercial potential of emerging therapies for the disease.

Questions answered

• How large is the diagnosed AA population, and how will its size change between 2023 and 2033? How large are the diagnosed alopecia totalis and universalis populations?
• What are the key unmet clinical needs in AA and to what degree will they be fulfilled by 2033?
• What is the current state of treatment in AA, and how will it evolve over time?
• What emerging AA therapies are viewed by treating dermatologists as most promising, and what sales / uptake will they achieve in AA? How will newer-to-market and emerging JAK inhibitors fit into the AA treatment algorithm?

Product description

Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key feature

Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Geography: United States and EU5.

Primary research: Six country-specific interviews with thought-leading dermatologists and supported by survey data collected for this study.

Epidemiology: Diagnosed incident cases, diagnosed incident cases by severity, diagnosed lifetime prevalent cases, and drug-treated prevalence by country.

Forecast: Drug-level sales and patient share of key AA therapies through 2033.

Emerging therapies: Coverage of key current and emerging therapies.